Psoriasis Management Approach

Initial Assessment and Treatment

The American Academy of Dermatology recommends classifying psoriasis severity as mild (less than 3% body surface area), moderate (3-10% body surface area), or severe (greater than 10% body surface area), considering both objective measures and subjective impact on quality of life 2
The National Psoriasis Foundation suggests assessing for psoriatic arthritis, but the details of this assessment are not provided in the cited text 1, 2

The American College of Dermatology recommends applying high-potency topical corticosteroids (Class 1-2) twice daily to thick plaques for maximum 2-4 weeks, combined with calcipotriol to achieve 58-92% clearance rates 1
The National Institute for Health and Care Excellence suggests using low-potency corticosteroids or topical calcineurin inhibitors on sensitive areas to minimize atrophy risk 1, 2

The British Association of Dermatologists recommends escalating to phototherapy when body surface area involvement exceeds 5%, or when there is inadequate response to optimized topical therapy after 8 weeks 1
The American Academy of Dermatology suggests that narrowband UVB is the first-line phototherapy with fewer side effects than PUVA 2
The National Psoriasis Foundation recommends that PUVA (psoralens plus ultraviolet A) is the least toxic systemic agent and should be considered first-line systemic treatment, starting at 70% of minimum phototoxic dose and increasing successive doses by 40% if no erythema develops 3, 4, 1, 2

The American College of Rheumatology recommends that the decision to move from topical to systemic treatment should be made by a senior dermatologist experienced in managing psoriasis, based on objective disease severity plus social and psychological factors 5, 4
The National Institute for Health and Care Excellence suggests that methotrexate should be started at 15 mg weekly, maximum 25-30 mg weekly, with response time of 2-6 weeks 1, 2
The British Association of Dermatologists recommends that cyclosporine should be dosed at 2.5-5 mg/kg daily, with response time of approximately 3 weeks 1, 2
The American Academy of Dermatology suggests that acitretin should be dosed at 25-50 mg daily, particularly effective for pustular psoriasis, with response as early as 3 weeks 1, 6, 2

The National Psoriasis Foundation recommends that biologics are recommended as an option for first-line treatment of moderate-to-severe plaque psoriasis because of their efficacy and acceptable safety profiles, although the details of this recommendation are not provided in the cited text 2
The American College of Dermatology suggests that TNF-α inhibitors (etanercept, adalimumab, certolizumab, infliximab) are first-line biologic therapy for psoriasis with associated arthritis 2
The British Association of Dermatologists recommends that biologics can be combined with methotrexate or topical high-potency corticosteroids, achieving treatment goals in 68.2-79.3% of patients by week 16 1

The American Academy of Dermatology recommends that hospital admission is required for patients presenting with generalized pustular or erythrodermic psoriasis due to risk of systemic involvement and potential mortality 5, 4, 6
The National Psoriasis Foundation suggests that infliximab demonstrates rapid and often complete disease clearance and should be considered first-line biologic therapy, with standard dosing of 5 mg/kg infused at weeks 0, 2, and 6, then every 8 weeks thereafter 1, 6

The British Association of Dermatologists recommends that systemic corticosteroids should never be prescribed for psoriasis—they precipitate erythrodermic psoriasis, generalized pustular psoriasis, or very unstable psoriasis when discontinued, potentially causing fatal deterioration 5, 1, 6, 2

The American College of Obstetricians and Gynecologists recommends that all commonly used systemic agents (methotrexate, cyclosporine, acitretin, biologics) are absolutely contraindicated in pregnancy 5, 4, 6, 2
The National Institute for Health and Care Excellence suggests that before prescribing to women of childbearing age, explicitly explain teratogenic risks and document that the patient understands the absolute necessity for reliable contraception 4, 6

The American Academy of Dermatology recommends that combination treatment with two or more systemic agents requires extreme caution because toxicity is at least additive—special attention should be paid to careful monitoring 5, 4, 2